{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T14:50:55Z","timestamp":1790607055987,"version":"4.1.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>\n                    Metyrapone is commonly used in the initial management of Cushing\u2019s syndrome to reduce hypercortisolemia, but its optimal dosage and timing can vary significantly between patients. Currently, there are limited guidelines on adjustment methods for its administration to individual needs. This study aimed to evaluate responsiveness of each patient to metyrapone and identify the patient characteristics associated with the indices of cortisol responsiveness following a low-dose metyrapone. This single-center retrospective observational study included 15 treatment-na\u00efve patients, 7 of whom had Cushing\u2019s disease and 8 had adrenal Cushing\u2019s syndrome. Serum cortisol levels were measured hourly from the time of administration of 250 mg of metyrapone up to four hours afterward. Parameters analyzed included the nadir of serum cortisol levels (F\n                    <jats:sub>nadir<\/jats:sub>\n                    ), the difference between basal and nadir serum cortisol levels (\n                    <jats:sub>\u0394<\/jats:sub>\n                    F), the time to nadir, and the characteristics of the patients. As a result, cortisol suppression curves showed significant variability among patients, particularly in the time to nadir. While the median time to nadir was 2 hours, 20% of patients required 4 hours or more, and these responses were not associated with patient characteristics. F\n                    <jats:sub>nadir<\/jats:sub>\n                    was positively correlated with early-morning serum cortisol levels, serum cortisol levels after low-dose dexamethasone suppression test (LDDST), and urinary free cortisol (UFC) levels, whereas\n                    <jats:sub>\u0394<\/jats:sub>\n                    F was positively correlated with late-night serum cortisol levels, serum cortisol levels after LDDST, and UFC levels. In conclusion, the duration of response to metyrapone appeared unpredictable in patients with Cushing\u2019s syndrome and did not correlate with patient characteristics at baseline. Tracking the effect of metyrapone following a single low-dose administration may explain this variability and provide insights for optimizing individual dosing regimens. Further studies are required to validate these findings and guide more personalized treatment adjustments.\n                  <\/jats:p>","DOI":"10.3389\/fendo.2024.1511155","type":"journal-article","created":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:11:02Z","timestamp":1734912662000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Metyrapone single administration, as a possible predictive tool of its dosage and timing in Cushing\u2019s syndrome"],"prefix":"10.3389","volume":"15","author":[{"given":"Yasutaka","family":"Tsujimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Bando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Ohmachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuma","family":"Motomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Oi-Yo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuriko","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Urai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiko","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genzo","family":"Iguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Fukuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.11305","article-title":"Cushing syndrome: A review","volume":"330","author":"Reincke","year":"2023","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61375-1","article-title":"Cushing\u2019s syndrome","volume":"386","author":"Lacroix","year":"2015","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-013-0511-3","article-title":"Characterization of persistent and recurrent Cushing\u2019s disease","volume":"17","author":"Sundaram","year":"2014","journal-title":"Pituitary"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1818","article-title":"Treatment of cushing\u2019s syndrome: an endocrine society clinical practice guideline","volume":"100","author":"Nieman","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.5444","article-title":"Diagnosis and management of pituitary adenomas: A review","volume":"329","author":"Tritos","year":"2023","journal-title":"JAMA"},{"key":"B6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1210\/clinem\/dgaa778","article-title":"Adrenally directed medical therapies for cushing syndrome","volume":"106","author":"Tritos","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","first-page":"101490","DOI":"10.1016\/j.beem.2021.101490","article-title":"Updates in adrenal steroidogenesis inhibitors for Cushing\u2019s syndrome - A practical guide","volume":"35","author":"Varlamov","year":"2021","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-022-01262-8","article-title":"Cushing\u2019s disease: adrenal steroidogenesis inhibitors","volume":"25","author":"Pivonello","year":"2022","journal-title":"Pituitary"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-018-0897-z","article-title":"Effectiveness of medical treatment for Cushing\u2019s syndrome: a systematic review and meta-analysis","volume":"21","author":"Broersen","year":"2018","journal-title":"Pituitary"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab048.1053","article-title":"Metyrapone treatment in endogenous cushing\u2019s syndrome: results at week 12 from PROMPT, a prospective international multicenter, open-label, phase III\/IV study","volume":"5","author":"Nieman","year":"2021","journal-title":"J Endocr Soc"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-2616","article-title":"Effectiveness of metyrapone in treating cushing\u2019s syndrome: A retrospective multicenter study in 195 patients","volume":"100","author":"Daniel","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1991.tb03517.x","article-title":"Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing\u2019s syndrome","volume":"35","author":"Verhelst","year":"1991","journal-title":"Clin Endocrinol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2017.00375","article-title":"Multiple salivary cortisol measurements are a useful tool to optimize metyrapone treatment in patients with cushing\u2019s syndromes treatment: case presentations","volume":"8","author":"Yoshida","year":"2017","journal-title":"Front Endocrinol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s11102-022-01218-y","article-title":"Glucocorticoid Withdrawal Syndrome following treatment of endogenous Cushing Syndrome","volume":"25","author":"He","year":"2022","journal-title":"Pituitary"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1807486","article-title":"Adrenal crisis","volume":"381","author":"Rushworth","year":"2019","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00136-7","article-title":"Adrenal insufficiency","volume":"397","author":"Husebye","year":"2021","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ando.2022.09.020","article-title":"Pneumocystis pneumonia in patients with Cushing\u2019s syndrome: A French multicenter retrospective study","volume":"84","author":"Lugat","year":"2023","journal-title":"Ann Endocrinol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1159\/000487713","article-title":"Clinical, diagnostic, and treatment disparities between HIV-infected and non-HIV-infected immunocompromised patients with pneumocystis jirovecii pneumonia","volume":"96","author":"Salzer","year":"2018","journal-title":"Respiration"},{"key":"B19","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1080\/14787210.2019.1671823","article-title":"Pneumocystis pneumonia in the twenty-first century: HIV-infected versus HIV-uninfected patients","volume":"17","author":"Cill\u00f3niz","year":"2019","journal-title":"Expert Rev Anti Infect Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-0125","article-title":"The diagnosis of Cushing\u2019s syndrome: an Endocrine Society Clinical Practice Guideline","volume":"93","author":"Nieman","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ12-0299","article-title":"Evaluation of the diagnostic criteria for Cushing's disease in Japan","volume":"60","author":"Kageyama","year":"2013","journal-title":"Endocr J"},{"key":"B22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11102-023-01362-z","article-title":"Newer parameters of the octreotide test in patients with acromegaly","volume":"27","author":"Urai","year":"2024","journal-title":"Pituitary"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-014-0580-y","article-title":"The prevalence and associated factors of colorectal neoplasms in acromegaly: a single center based study","volume":"18","author":"Yamamoto","year":"2015","journal-title":"Pituitary"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1511155\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:11:05Z","timestamp":1734912665000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1511155\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,23]]},"references-count":23,"alternative-id":["10.3389\/fendo.2024.1511155"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2024.1511155","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,23]]},"article-number":"1511155"}}